Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987027 | 0.90 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL21014734 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL20986992 | 0.89 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL20987046 | 0.88 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL20987073 | 0.88 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL20987001 | 0.85 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL27523706 | 0.83 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Pyrophosphoric Acid SCHEMBL31756913 | 0.82 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL21014314 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL21014844 | 0.80 | CYP3A4 (0.64) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481827-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2021-11-03 | — | — | EP | claimed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | claimed |
| EP-3481827-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | HRH2, GIPR, HRH4 | CYP3A4 145/4885CYP2C9 477/4885CYP2D6 327/4885 |
| US-20190152971-A1 | Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof | GIPR, PGC, VIP | CYP3A4 987/4885CYP2C9 1375/4885CYP2D6 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.